PCI Biotech Reports Successful Completion Of Second Dose Group In Pivotal Amphinex(R) Trial

Links shared publicly online about this topic.

  • 1,444
    total visits

PCI Biotech Reports Successful Completion Of Second Dose Group In Pivotal Amphinex(R) Trial

medicalnewstoday.com —

Pci biotech as ( pcib.ol) (ose:pcib) reported today that it has completed the successful treatment of the second dose group in the phase i/ii study of its proprietary photosensitiser amphinex®

View full resource at medicalnewstoday.com

Tags: Biotech

  • Share

Most Recently Shared on January 19, 2010 at 7:18 pm By:

mnt_cancer MNT Cancer News

PCI Biotech Reports Successful Completion Of Second Dose Group In Pivotal Amphinex(R) Trial http://mnt.to/3wvF

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

medical_tweets medical_tweets

MNT Clinical Trials MNT Clinical Trials

Advertisement